Search

Frank Peter Stegmeier

from Acton, MA
Age ~50
Get Report
Also known as:
Frank P Stegmeier
Phone and address:
20 Kinsley Rd, Acton, MA 01720
(978) 429-8425
Related to:
Melvin Oliver, 75
Connected to:
Cynthia K Stegmeier, 72John J Stegmeier, 54Paul B Stegmeir, 82Randolph J Stegmeier, 75Wayne P Stegmeier, 75Scott G Stegmiller, 44Stephanie L Stegmuller, 50Adam J Stegner, 62Amy E Stegner, 71Bernard P Stegner, 102

Frank Stegmeier Phones & Addresses

  • 20 Kinsley Rd, Acton, MA 01720 (978) 429-8425
  • Franconia, NH
  • 224 Jamaicaway, Jamaica Plain, MA 02130 (617) 524-4434
  • 334 Harvard St, Cambridge, MA 02139 (617) 868-5332
  • Imnaha, OR

Work

Company: Ksq therapeutics Dec 2015 Position: Chief scientific officer

Education

School / High School: Harvard University 2004 to 2007 Specialities: Genetics, Biology

Skills

Drug Discovery • Genomics • Functional Genomics • Cancer Biology • Target Discovery • Assay Development • High Throughput Screening • Validation • Cell • Western Blotting • Biochemistry • Cell Biology • Bioinformatics • Flow Cytometry • Genetics • In Vivo • Drug Development • Immunology • Confocal Microscopy • Molecular Biology • Oncology • Animal Models • Cancer • Biomarker Discovery • Biotechnology • Lifesciences • Protein Purification • Cell Culture • In Vitro • Protein Chemistry • Molecular Cloning • Pharmacology • Protein Expression • Stem Cells • Biomarkers • Tissue Culture • Qpcr • Life Sciences

Industries

Pharmaceuticals

Public records

Vehicle Records

Frank Stegmeier

View page
Address:
20 Kinsley Rd, Acton, MA 01720
Phone:
(617) 375-8852
VIN:
1HGFA16847L054244
Make:
HONDA
Model:
CIVIC
Year:
2007

Resumes

Resumes

Frank Stegmeier Photo 1

Chief Scientific Officer

View page
Location:
20 Kinsley Rd, Acton, MA 01720
Industry:
Pharmaceuticals
Work:
Ksq Therapeutics
Chief Scientific Officer
Novartis Jun 2010 - Nov 2015
Head of Cambridge Target Validation, Oncology
Novartis Apr 1, 2013 - Nov 2013
Director, Head of Cambridge Target Validation, Oncology
Novartis Apr 2007 - Aug 2010
Research Investigator, Oncology
Harvard Medical School 2004 - 2007
Postdoctoral Fellow
Education:
Harvard University 2004 - 2007
Massachusetts Institute of Technology 1999 - 2004
Doctorates, Doctor of Philosophy, Biology University of Tübingen 1996 - 1999
Bachelors, Bachelor of Science, Biochemistry
Skills:
Drug Discovery
Genomics
Functional Genomics
Cancer Biology
Target Discovery
Assay Development
High Throughput Screening
Validation
Cell
Western Blotting
Biochemistry
Cell Biology
Bioinformatics
Flow Cytometry
Genetics
In Vivo
Drug Development
Immunology
Confocal Microscopy
Molecular Biology
Oncology
Animal Models
Cancer
Biomarker Discovery
Biotechnology
Lifesciences
Protein Purification
Cell Culture
In Vitro
Protein Chemistry
Molecular Cloning
Pharmacology
Protein Expression
Stem Cells
Biomarkers
Tissue Culture
Qpcr
Life Sciences

Publications

Us Patents

Use Of A Pkc Inhibitor

View page
US Patent:
20110245256, Oct 6, 2011
Filed:
Mar 28, 2011
Appl. No.:
13/073652
Inventors:
Walter SCHULER - Basel, CH
Frank P. STEGMEIER - Acton MA, US
Markus WARMUTH - Natick MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 31/499
A61K 31/517
A61K 31/404
A61P 35/00
US Classification:
514249, 51425217, 514414
Abstract:
The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence, provided herein is a method for inhibiting the growth of B-cell lymphoma having chronic active B-cell-receptor signaling, or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling, by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B-cell lymphoma having chronic active B-cell-receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.

Compositions And Methods To Treat Cancer

View page
US Patent:
20210155932, May 27, 2021
Filed:
Jul 20, 2018
Appl. No.:
16/632777
Inventors:
- Basel, CH
Antoine DEWECK - Basel, CH
Javad GOLJI - Cambridge MA, US
Gregory HOFFMAN - Cambridge, MA
Francesco HOFMANN - Basel, CH
Audrey KAUFFMANN - Basel, CH
Konstantinos John MAVRAKIS - Cambridge MA, US
William SELLERS - Cambridge MA, US
Tobias SCHMELZLE - Basel, CH
Frank Peter STEGMEIER - Cambridge MA, US
International Classification:
C12N 15/115
C12N 15/113
C12N 9/22
A61K 45/06
G01N 33/574
Abstract:
The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Combination Gene Targets For Improved Immunotherapy

View page
US Patent:
20200347386, Nov 5, 2020
Filed:
Feb 4, 2020
Appl. No.:
16/781732
Inventors:
- Cambridge MA, US
Michael SCHLABACH - Cambridge MA, US
Gregory KRYUKOV - Cambridge MA, US
Anne Louise CADZOW - Cambridge MA, US
Isabelle Fleur LE MERCIER - Cambridge MA, US
Frank STEGMEIER - Cambridge MA, US
International Classification:
C12N 15/11
C12N 9/22
C12N 15/86
A61K 35/17
A61K 49/00
C12N 5/0783
Abstract:
The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.

Organic Compositions To Treat Hsf1-Related Diseases

View page
US Patent:
20190323008, Oct 24, 2019
Filed:
Jun 24, 2019
Appl. No.:
16/450967
Inventors:
- Pasadena CA, US
Kalyani Gampa - Natick MA, US
Dieter Huesken - Freiburg i. Br, DE
Frank Stegmeier - Acton MA, US
Mark Stump - Lexington MA, US
Chandra Vargeese - Schwenksville PA, US
Jan Weiler - Lorrach-Haagen, DE
Wenlai Zhou - Newton MA, US
International Classification:
C12N 15/113
A61K 31/5377
A61K 45/06
A61K 31/713
Abstract:
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Organic Compositions To Treat Beta-Catenin-Related Diseases

View page
US Patent:
20180282728, Oct 4, 2018
Filed:
Jun 13, 2018
Appl. No.:
16/007517
Inventors:
- Pasadena CA, US
David Anton Bumcrot - Cambridge MA, US
Dieter Huesken - Freiburg I. Br., DE
Satyanarayana Kuchimanchi - Cambridge MA, US
Stuart Milstein - Cambridge MA, US
Frank Peter Stegmeier - Acton MA, US
Markus Warmuth - Natick MA, US
Jan Weiler - Cambridge MA, US
International Classification:
C12N 15/113
A61K 31/713
Abstract:
The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

Biomarkers Associated With Brm Inhibition

View page
US Patent:
20180258491, Sep 13, 2018
Filed:
Dec 22, 2017
Appl. No.:
15/853699
Inventors:
Zainab JAGANI - Cambridge MA, US
Gregory HOFFMAN - Cambridge MA, US
Frank Peter STEGMEIER - Acton MA, US
Craig Stephen MICKANIN - Cambridge MA, US
Assignee:
Novartis AG - Basel
International Classification:
C12Q 1/6886
C12N 15/113
G01N 33/574
Abstract:
The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate FIRM inhibitors, and associated methods of treatment are also provided.

Organic Compositions To Treat Kras-Related Diseases

View page
US Patent:
20180153919, Jun 7, 2018
Filed:
Sep 7, 2016
Appl. No.:
15/258042
Inventors:
- Pasadena CA, US
Stuart Milstein - Cambridge MA, US
Ivanka Toudjarska - Cambridge MA, US
Earl McDonald - Cambridge MA, US
Michael Schlabach, JR. - Cambridge MA, US
Frank P. Stegmeier - Acton MA, US
Markus Warmuth - Cambridge MA, US
Kalyani Gampa - Natick MA, US
Dieter Huesken - Freiburg i. Br., DE
Mark Stump - Lexington MA, US
Jan Weiler - Newton MA, US
Zainab Jagani - Brookline MA, US
International Classification:
A61K 31/713
A61K 45/06
A61K 47/54
C12N 15/113
Abstract:
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

Inhibition Of Prmt5 To Treat Mtap-Deficiency-Related Diseases

View page
US Patent:
20180010132, Jan 11, 2018
Filed:
Sep 9, 2015
Appl. No.:
15/510542
Inventors:
- Basel, CH
Frank Peter STEGMEIER - Acton MA, US
Assignee:
Novartis AG - Basel
International Classification:
C12N 15/113
A61K 45/06
A61K 31/7088
C07K 16/40
A61K 39/395
G01N 33/574
A61K 39/00
Abstract:
The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is MTAP-deficient and/or MTA-accumulating and thus amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.
Control profile
Frank Peter Stegmeier from Acton, MA, age ~50 Get Report